

Scientific Think Tank Participants

Advances in Controlled release for depot and implant technology/s, as it applies to creating non-surgical alternatives to sterilize dogs and cats

April 17 – 19th, 2012

Larry Acquarulo, PhD, CPD

Founder & CEO, Foster Corporation, Putnam, CT • www.fostercomp.com

Larry is the founder and CEO of Foster Corporation, a developer and manufacturer of critical polymer compounds for medical devices and drug delivery. Incorporated in 1989, Foster is headquartered in Putnam CT, with a west coast facility in Las Vegas, Nevada. Foster specializes in melt extrusion blending and forming of highly regulated materials including implantable polymers and bioresorbable drug delivery polymers used in combination devices, controlled release delivery systems and pharmaceuticals.



Larry received a Bachelor's degree in Plastics Engineering from the University of Massachusetts Lowell, a master's degree in Material Science from The University of Connecticut, a PhD in Engineering Management from Kennedy Western University, Thousand Oaks, CA (non-accredited university) and most recently a CPD in Business Strategy from the Wharton School, University of Pennsylvania.

Larry has six US and international patents in the field of nano composites, cross-linkable polymers, lubricated and drug-filled polymers for medical device and industrial use, and has published over one dozen technical papers in leading journals such as *Medical Device and Diagnostic Industry Magazine*, *Modern Plastics*, *Plastics Engineering Magazine*, *Design News*, and *Medical Plastics and Biomaterials*.

In addition, Larry is a co-owner of Pelham Plastics making custom made catheters, injection molding and assembly of medical devices, and co-owner, Putnam Plastics making comprehensive medical tubing extrusion. He is also a board member of BEACON, Biomedical Engineering Consortium www.beaconalliance.org and actively involved with the Institute of Materials Science (IMS), University of Connecticut, The Society of Plastics Engineers and Vistage CEO Group. Larry has two grown up children and lives in Lisbon, Ct with his wife Cheryl and dog Sandy.

Joyce Briggs, MS

President, Alliance for Contraception in Cat and Dogs, Portland, OR • www.acc-d.org

Joyce has been involved in a leadership capacity with ACC&D full time since 2006. She has helped substantially advance interest in, work toward, and support for creating non-surgical sterilants for progressive population control of cats and dogs. She has led the organization's strategic planning, fundraising, and program development, established a respected Scientific Advisory Board, and produced and directed two major scientific symposiums and now four scientific think tanks. She has played a key cultivation role in developing strategic partnerships advancing this field.



Joyce has worked in national animal welfare for seventeen years, through top general management, marketing, development, program and public relations positions at national nonprofit organizations, and as a management consultant bridging nonprofits, corporations and communities. As executive director of PetSmart Charities from 1999 - 2004, Joyce developed and oversaw the grants program which raised and distributed \$23 million. Through adoption centers in over 620 PetSmart stores, PetSmart Charities found homes for over 1.2 million once-homeless pets in that time. Joyce was senior director of marketing and PR for the American Humane Association. She served on the Board of Directors for the Delta Society for three years and is active with the Animal Shelter Alliance of Portland (ASAP). Prior to working full-time in animal protection, she held corporate positions for 15 years. Her career spans management positions with New York City advertising agencies, including Ogilvy & Mather, and marketing leadership positions with Nabisco, Nutri-System and the Franklin Mint. She holds a master's degree in advertising from Northwestern University.

Michael McDonald Crowley, PhD

President, Theridian Technologies, LLC, Austin Texas • www.theridian.com

Michael is President of Theridian Technologies, LLC and most recently served as Vice President, Business Development at PharmaForm. In these capacities, he successfully licensed and out licensed both product and drug delivery technologies, secured \$34M in service contracts, completed 2 asset transactions and was technical lead for several drug products. During Michael's tenure at PharmaForm he has also held the positions of Vice President, Quality Control and Analytical Research and Development and Vice President, Drug Delivery Technology and Manufacturing Services. Dr. Crowley has worked in the field of drug delivery and pharmaceutical research for more than 19 years and has previously been employed in senior management roles with Monsanto Company, Warner-Jenkinson Company and Mission Pharmacal.



Michael received his B.S. degree in Chemistry from the University of Missouri at St. Louis, an M.A. in Organic Chemistry from Washington University and a PhD in Pharmaceutics from The University of Texas at Austin where he studied under Professor James McGinity. His research interests include physical pharmacy and pharmaceutical technology focused on novel drug delivery systems. Dr. Crowley has presented his work in several national and international scientific symposia and conferences. He has authored peer reviewed publications on topics such as hot-melt extrusion, polymer stability, protein binding, analytical characterization of dosage forms, pulmonary drug delivery and the mechanical properties of films. Dr. Crowley authored a chapter for the 2005 edition of Remington: The Science and Practice of Pharmacy. Dr. Crowley is a co-inventor on nine patents and patent applications, is a member of the Editorial Advisory Board for American Pharmaceutical Outsourcing, and has served as a reviewer for several scientific journals.

Linda A. Felton, PhD

Chair, Department of Pharmaceutical Sciences and Associate Professor of Pharmaceutics
University of New Mexico College of Pharmacy, Albuquerque, NM

Linda is an Associate Professor of Pharmaceutics and Chair of the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of New Mexico. She earned a B.S. in Pharmacy and a Ph.D. in Pharmaceutics from the University of Texas at Austin. Her research interests are focused on polymeric film coating technology, modified release systems, and topical/transdermal drug delivery. She has presented her work at national and international conferences and has published extensively in peer-reviewed journals. Dr. Felton is an editorial board member of Drug Development and Industrial Pharmacy, the Manufacturing section editor of the 22nd edition of "Remington: The Science and Practice of Pharmacy", and the co-editor of the 3rd edition of "Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms". Dr. Felton has a joint appointment with the Department of Veterans Affairs Cooperative Studies Program where she oversees the formulation development of clinical trials materials. She is a current member of the American Association of Pharmaceutical Scientists, the Controlled Release Society, and the International Society for Pharmaceutical Engineering.



Gary E. Gamerman, MS, JD

President, Seraphim Life Sciences Consulting LLC, Vienna VA • www.SeraphimLifeSciences.com



Gary has a varied background spanning 22+ years in bio/pharmaceutical and medical device and company development, including scientific/engineering, clinical/regulatory, manufacturing/operations, sourcing/supply chain, legal/IP, distribution/marketing, executive management, and diligence assessment. He consults for a wide range of life sciences companies, foundations and investors. He serves as an expert witness and arbitrator in a range of disputes involving medical products, including matters involving several billion dollars in litigated claims.

He is noted for integrating a wide spectrum of experience in technical, regulatory/legal, operational and commercial issues with creativity and zeal to solve difficult challenges.

His work was instrumental to current approaches in dealing with complex regulatory/development obstacles, including the "animal" rule for medical defense products, biogenerics/biosimilars, well characterized biologics.

He has held executive leadership positions for several emerging biopharmaceutical companies, including MonoGen, Iatros, and GenTox. Prior to founding Seraphim, he was an attorney in the FDA/Life Sciences practices of two international law firms, where he counseled leading companies and venture firms in the development, licensing and regulation of biologics, pharmaceuticals, and medical devices. He served at FDA/CBER as reviewer for vaccines, biopharmaceutics and diagnostics, and as a researcher in academic (Johns

Hopkins and University of Iowa) and corporate settings. He holds graduate and professional degrees in law, biochemistry, and applied molecular biology.

Gary devotes a large portion of his efforts to foundations and not-for-profit organizations that focus on public and animal health and contraception, including Afaxys, Parsemus, Ipas/WomanCare Global, Found Animals Foundation, the Institute for One World Health and several of the largest health foundations committed to public health technology and access. His work with those organizations principally focuses on establishment of reliable supply of affordable contraceptives and other medical products.

Shirley D. Johnston, DVM, PhD, DACT

Director of Scientific Research, Found Animals Foundation, Los Angeles, CA
<http://michelson.foundanimals.org/>



Shirley was educated at the University of Washington (BS), Washington State University (DVM), and the University of Minnesota (PhD). She is a diplomat of the American College of Theriogenologists (ACT), the veterinary specialty board for animal reproduction, and was ACT's first woman president. She has academic faculty experience in canine and feline reproductive endocrinology and administrative experience at the University of Minnesota and Washington State University. She was the founding dean of the 28th College of Veterinary Medicine in the United States, the College of Veterinary Medicine at Western University of Health Sciences, Pomona, California. Prior to joining Found Animals in 2009, she was Vice President of University Advancement at Western University. She is the senior author of Johnston SD, Root Kustritz MV, Olson PNS: *Canine and Feline Theriogenology*, WB Saunders Co., Philadelphia, 2001.

Viraj Mane, PhD

Faculty Research Associate
Institute for Bioscience and Biotechnology Research at the University of Maryland, College Park, MD

Viraj obtained his PhD from Baylor College of Medicine in Houston, TX. Dr. Mane conducted his graduate research in the Department of Molecular and Human Genetics where he demonstrated curative gene therapy in various rodent disease models using engineered viruses, leading to 11 scientific publications. Upon graduation, Dr. Mane undertook a postdoctoral fellowship at the US Food and Drug Administration to develop methods to analyze the activation of human interferon genes. There, he developed a novel assay (which was licensed to a biotechnology company) and co-authored the resulting patent and 2 research publications. Dr. Mane is currently a faculty research associate in the Institute for Bioscience and Biotechnology Research at the University of Maryland, where he studies intravenous and intraoral delivery of targeted therapeutic nanoparticles in cell culture and animal models. In addition, he is filing a patent describing an apheresis-related medical device and is competing in a campus-wide business plan competition with the hope of commercializing this device. He has also pursued artistic



interests by providing creative design consulting services to Children's National Medical Center in Washington, DC, a nonprofit group serving in Haiti, and an independent filmmaker in New York City. His film poster artwork was selected for inclusion at the National Library of Congress in Washington, DC.

David Petrick VMD, JD

The Delta Consortium, Princeton, NJ



Dave has over 25 years of experience in bringing novel animal health products to the marketplace. Dr. Petrick has worked in Regulatory Affairs and Product Development for both American Cyanamid Company and Schering-Plough Animal Health during his professional career. In 2004, he founded the Delta Consortium Regulatory Consulting, Limited, serving as a consultant in Regulatory Affairs for animal health companies. In 2009, he joined Triveritas, and was a part of the opening of Triveritas, USA.

He also currently serves as Vice President Regulatory Affairs for Velcera Pharmaceuticals. Dr. Petrick holds a degree in veterinary medicine from the University of Pennsylvania, and a law degree from Seton Hall University. He is a member of the American Veterinary Medical Association, the American Bar Association, the New Jersey Bar Association and the New Jersey Bar.

Dr. Satya Prakash, PhD

Professor, McGill University, Co-Founder and Director, Micropharma, Montreal, Quebec, Canada

Satya is Director, Biomedical Technology and Cell Therapy Research Laboratory and Professor, Biomedical Engineering, Artificial Cells and Organs Research, Physiology, and Experimental Medicine at Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

He has published more than 225 peer-reviewed articles/abstracts, been listed as an inventor in 45 approved/pending patents, edited 2 books, and contributed 18 book chapters presented more than 80 invited talks across the globe. Dr. Prakash is the winner of 28 awards including "Medial for Outstanding Contribution to the Advancement of Science", Overseas Scholar, Fraser, Monat and McPherson Award, FRSQ Chercheure Boursière Award and the Canadian Institute of Health Research (CIHR) Investigator Award. At McGill Dr. Prakash's research has generated multi millions in individual and collective research grants and he has trained more than 50 graduate students, visiting scholars, post-doctoral fellows, undergraduate and fellows. Currently his team is conducting major research in the areas of probiotics, microencapsulation, nanoencapsulation, artificial cells, drug targeting, siRNA, cell delivery, nanomedicine, kidney substitutes, colon cancer, fatty liver, breast cancer, diabetes, stent design, wound healing and other human health and technology developments. Dr. Prakash serves as Regional Editor (Americas), Assistant Editor and Editorial board of various journals and serves to various panels including, CIHR, Ontario Advance Health Technology, Alberta Ingenuity and other panels. Dr. Prakash holds a



B.Sc. (H), M.Sc., M. Tech., Ph.D. and D.Sc. degrees. Dr. Satya Prakash is co-founder of Micropharma and serves as Director.

Linda Rhodes, VMD, PhD

CEO, Aratana Therapeutics, Inc., Kansas City, KS

Linda has 25 years of accomplishments in human and animal drug discovery, development, biomedical research and clinical veterinary medicine. She has an extensive background in physiology, medicine, molecular biology, and drug discovery and development. As a senior research fellow at Merck Research Laboratories for 10 years, Linda led pre-clinical biology efforts for several marketed human drugs. She practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd., as director of development projects, leading project teams developing novel compounds for a variety of indications.



In April 2001 Rhodes co-founded AlcheraBio, a contract research organization specializing in animal health drug development and marketing which has clients in the US, EU, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, a formulations and contract manufacturing company that specializes in animal health, and Rhodes then held the position of Vice President - Clinical Research. In February, 2011, she was named the CEO of Aratana Therapeutics, a venture capital backed animal health start-up company that will be developing novel therapies for animals.

Rhodes received her BA at Sarah Lawrence College, VMD at the University of Pennsylvania School of Veterinary Medicine and completed her PhD in reproductive physiology at Cornell University with funding from the NIH.

##

The Alliance for Contraception in Cats & Dogs (ACC&D) is a nonprofit 501(c)(3) whose mission is to expedite the successful introduction of methods to non-surgically sterilize dogs and cats and to support the distribution and promotion of these products to humanely control cat and dog populations worldwide. ACC&D works to advance science; network animal welfare, animal health, and public health stakeholders; and provide scientifically sound, animal welfare-oriented information on the field of non-surgical fertility control for cats and dogs.

To learn more about the mission and work of ACC&D, visit or find us on Facebook.